Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-CCR5 agents and methods of treatment to block cancer metastasis or enhance cell death induced by DNA damage chemotherapy

A cancer and drug technology, applied in chemical instruments and methods, receptors/cell surface antigens/cell surface determinants, anti-tumor drugs, etc., can solve problems such as unmet needs and unproven clinical treatment plans

Pending Publication Date: 2022-07-08
西托戴恩股份有限公司
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, there have been multiple approaches that have attempted to improve the care of patients with triple-negative breast cancer, including DNA-damaging agents (such as platinum), inhibitors targeting EGFR and VEGF, and PARP inhibitors; however, none of the therapies have performed as expected in the clinic To be successful, more targeted therapies need to be developed and explored [Aysola 2013]
Thus, metastatic TNBC is a complex disease with unmet needs and unproven clinical treatment options

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CCR5 agents and methods of treatment to block cancer metastasis or enhance cell death induced by DNA damage chemotherapy
  • Anti-CCR5 agents and methods of treatment to block cancer metastasis or enhance cell death induced by DNA damage chemotherapy
  • Anti-CCR5 agents and methods of treatment to block cancer metastasis or enhance cell death induced by DNA damage chemotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0161] Example 1. Binding of lelimumab to CCR5 expressed in breast cancer cells

[0162] Figure 1A and Figure 1B : Lelimumab binds to CCR5 in human breast cancer cells.

[0163] like Figure 1A As shown, to determine the binding of lelimumab to human CCR5 in breast cancer cells, the MDA-MB-231 human breast cancer cell line was transfected with the human CCR5 expression vector as a model system. CCR5 positive cells were assessed using a previously tested commercial APC-conjugated mouse anti-human / mouse / rat CCR5 antibody (FAB1802A) (APC-αCCR5) from R&D as a positive control. MDA-MB-231-CCR5 cells were stained with APC-αCCR5 and lelimumab using concentrations of 1-140 g / ml. Mouse anti-human IgG conjugated to Alexa Fluor 488 was used as the secondary antibody to measure lelimumab binding to cells. Figure 1A Analysis of lelimumab binding to CCR5 by FACS is shown in . Binding of lelimumab to human CCR5 was demonstrated.

[0164] like Figure 1B As shown, the efficiency of ...

Embodiment 2

[0165] Example 2. Effect of PRO140 on CCL5-induced Ca in MDA-MB-231-CCR5 cells 2+ Effects of ionic reactions

[0166] Figure 2A , Figure 2B , Figure 2C and Figure 2D : PRO140 (lelimumab) blocks human CCR5-mediated signaling in human breast cancer cells. CCR5 activation induces calcium flux (Mueller et al., 2002; Petkovic et al., 2004). To assess the effect of tetralimumab on CCR5 function, we analyzed live cell images ( Figure 2A , Figure 2B and Figure 2C ) measured the calcium response induced by CCL5 in MDA-MB-231-CCR5 cells in the presence or absence of lelimumab. Fluo-4 was used as a calcium concentration indicator. The CCR5 antagonist velivero was used as a positive control ( Figure 2A and Figure 2D ). The results showed that lelimumab was able to block CCL5-induced calcium responses in MDA-MB-231-CCR5 cells (1.23±0.10 for control cells, N=10, and 0.54±0.13 for PRO140-treated cells, N=12. CCL5 induced calcium peak (P<0.001).

Embodiment 3

[0167] Example 3. Lelimumab blocks 3D Matrigel invasion of breast cancer cells

[0168] Figure 3A , Figure 3B , Figure 3C and Figure 3D : Lelimumab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. The ability of breast cancer cells to invade the extracellular matrix differs from, but is an important step in, tumor metastasis (Zetter, 1990). To test the ability of PRO140 to block the 3D Matrigel invasion assay, MDA-MB-231 cells were used. CCL5 acts as a chemokine to induce invasion. Velivero, a small molecule inhibitor of CCR5, was used as a form of positive control. Lelimumab reduces CCL5-induced invasion of MDA-MB-231 breast cancer cells with similar efficacy to veliverol ( Figure 3A , Figure 3B ) (855±9 for control, N=8, 855±9 for lelimumab, N=9, P Figure 3C , Figure 3D ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates to the use of a DNA damaging agent and a lelizumab (PRO 140) or other anti-CCR5 agent for treating or preventing cancer metastasis and enhancing the cell killing ability of a DNA damaging agent by selectively targeting the CCR5 receptor. The present disclosure relates to the use of a DNA disrupting agent and Lellizumab (PRO 140) or other anti-CCR5 agent to treat or prevent cancer metastasis and reduce circulating tumor cells (CTCs) or presumed metastatic tumor cells in post-treatment peripheral blood, reduce CCR5 expression on cancer-related cells after treatment, reduce tumor volume after treatment. The disclosure may be used to treat or prevent subjects with cancer, particularly subjects with metastatic CCR5 + cancer.

Description

Background technique [0001] For cancer, studies have shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of the disease state of several cancers. Published studies have shown that blocking CCR5 reduces tumor metastasis in laboratory and animal models of aggressive breast and prostate cancer. [0002] Several studies have shown that CCR5 signaling has antitumor effects, acts as a costimulatory molecule for T cell activation, and increases T cell chemotaxis to the tumor microenvironment. See Gao et al, CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells, OPEN BIOL., 6: 160122 (2016); González-Martín et al, CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells, ONCOIMMUNOLOGY, 1:106-108 (2012). However, there is also evidence that CCL5 / CCR5 axis signaling may be preferentially activated in certain types of cancer, such as breast and prostate canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705
CPCC07K16/2866A61K2039/812A61K31/555A61K39/39558A61K2039/505A61K2039/545C07K2317/24A61K45/06A61K31/704A61K31/282A61P35/00A61P35/04A61K2300/00
Inventor R·G·派斯特尔S·凯利
Owner 西托戴恩股份有限公司